Lisinopril Complete Drug-Drug Interaction Profile

How Lisinopril Works: The Mechanism Behind Every Interaction

Lisinopril blocks angiotensin-converting enzyme (ACE), which converts angiotensin I to angiotensin II and simultaneously degrades bradykinin. The downstream effects of lower angiotensin II and higher bradykinin explain almost every clinically meaningful drug interaction the molecule produces.

The Renin-Angiotensin-Aldosterone Axis

ACE inhibition reduces angiotensin II, which in turn suppresses aldosterone secretion from the adrenal cortex. Aldosterone normally drives sodium retention and potassium excretion in the distal nephron. Without aldosterone's effect, potassium accumulates. Any co-administered drug that also raises potassium, reduces renal perfusion, or further suppresses aldosterone adds directly to that burden [1].

The FDA-approved labeling for lisinopril specifically warns that drugs affecting the renin-angiotensin-aldosterone system (RAAS) in combination can cause "hypotension, hyperkalemia, and changes in renal function including acute renal failure" [2].

Bradykinin Accumulation and Why It Matters for Interactions

ACE also degrades bradykinin. When ACE is inhibited, bradykinin rises, producing vasodilation via nitric oxide and prostaglandins. Drugs that block prostaglandin synthesis, including NSAIDs and COX-2 inhibitors, therefore blunt this part of lisinopril's antihypertensive action. The cough associated with ACE inhibitors is a direct bradykinin effect, and it is also worsened by drugs that raise tissue bradykinin independently.

Renal Efferent Arteriole Dependence

Under states of reduced renal perfusion (heart failure, volume depletion, bilateral renal artery stenosis), glomerular filtration depends on angiotensin II constricting the efferent arteriole to maintain intraglomerular pressure. Lisinopril removes that constriction. Any drug that also reduces renal perfusion pressure, such as NSAIDs reducing prostaglandin-mediated afferent dilation, or diuretics producing volume depletion, compounds the risk for acute kidney injury [3].

Potassium-Raising Drug Combinations: The Most Common Serious Interaction

Hyperkalemia is the most frequently encountered serious adverse effect of lisinopril, and it is almost always driven by co-administration of a potassium-sparing agent. Serum potassium above 5.5 mEq/L occurred in 2.2% of patients in the ATLAS trial of lisinopril in heart failure, rising sharply when spironolactone was added [4].

Potassium-Sparing Diuretics

Spironolactone, eplerenone, amiloride, and triamterene all reduce renal potassium excretion through separate mechanisms from ACE inhibition, but the net effect stacks directly. The RALES trial demonstrated that adding spironolactone 25 mg to an ACE inhibitor in systolic heart failure reduced mortality by 30% but increased the rate of serious hyperkalemia to 2% when proper monitoring was used [5]. In routine post-marketing practice, a 2004 NEJM analysis showed that spironolactone prescriptions after RALES publication rose 5-fold and hyperkalemia-related hospitalizations and deaths rose in parallel, reaching a rate of 10.4 per 1,000 patients versus 2.4 per 1,000 before RALES [6].

The clinical instruction: check serum potassium and creatinine at baseline, at 1 week, and at 1 month after any potassium-sparing diuretic is added. Target potassium <5.0 mEq/L.

Oral Potassium Supplements

Even modest supplementation (20 mEq/day of KCl) can push a patient on lisinopril above the safe threshold, particularly if baseline renal function is reduced. Hold or reduce supplement doses whenever potassium exceeds 4.5 mEq/L in patients with eGFR <60 mL/min/1.73 m².

Trimethoprim and Trimethoprim-Sulfamethoxazole

Trimethoprim blocks the epithelial sodium channel (ENaC) in the distal tubule, functionally behaving like amiloride. A 2010 BMJ study (N=6,903 matched pairs) found that patients on ACE inhibitors who filled a trimethoprim-sulfamethoxazole prescription had a 6.7-fold increase in sudden death risk compared to those dispensed nitrofurantoin, with the excess risk concentrated in patients already on a RAAS agent [7]. At standard doses of 160/800 mg twice daily for 7 to 10 days, this interaction is clinically significant. Choose nitrofurantoin or cephalexin for uncomplicated urinary tract infections in patients taking lisinopril when possible.

NSAIDs and COX-2 Inhibitors: Blunted Efficacy and Kidney Risk

NSAIDs reduce blood pressure control and raise the risk of acute kidney injury when combined with lisinopril. This pairing is extremely common in older adults managing hypertension alongside musculoskeletal pain.

Antihypertensive Attenuation

Prostaglandins contribute to afferent arteriolar dilation and sodium excretion. NSAIDs block this, causing sodium and water retention that raises blood pressure by 3 to 5 mmHg on average across multiple meta-analyses [8]. The interaction is dose-dependent and present with both non-selective NSAIDs (ibuprofen, naproxen, indomethacin) and selective COX-2 inhibitors (celecoxib).

Acute Kidney Injury: The "Triple Whammy"

Prescribers in nephrology frequently refer to the combination of an ACE inhibitor, a diuretic, and an NSAID as the "triple whammy." Each drug individually poses moderate renal risk. Together, they reduce afferent perfusion (NSAID), reduce efferent constriction (ACE inhibitor), and reduce intravascular volume (diuretic) simultaneously. A 2013 BMJ study (N=487,372 person-years) found the adjusted rate ratio for acute kidney injury in patients on all three drugs was 1.31 compared to any single agent alone, with absolute risk concentrated in the first 30 days [9].

Acetaminophen at standard doses (up to 3 g/day in adults without liver disease) does not block prostaglandins significantly and is the preferred analgesic for patients on lisinopril who need regular pain management.

Dual RAAS Blockade: ARBs and Aliskiren

Combining lisinopril with an angiotensin receptor blocker (ARB) such as losartan or valsartan, or with the direct renin inhibitor aliskiren, constitutes dual RAAS blockade. The rationale seemed attractive, targeting two points on the same cascade for greater efficacy.

The ONTARGET Evidence Against Dual Blockade

The ONTARGET trial (N=25,620) compared telmisartan plus ramipril to either agent alone in patients at high cardiovascular risk. The combination produced no additional reduction in cardiovascular events but significantly increased hypotension, syncope, renal impairment, and hyperkalemia [10]. The rate of dialysis or doubling of serum creatinine was 13.5% in the combination arm versus 10.2% with ramipril alone (P<0.001).

The 2014 FDA Drug Safety Communication specifically advises against combined ACE inhibitor plus ARB therapy for most patients and prohibits the combination of aliskiren with ACE inhibitors in patients with diabetes or eGFR <60 mL/min/1.73 m² [2].

Sacubitril/Valsartan (Entresto): A 36-Hour Washout Requirement

Sacubitril inhibits neprilysin, the enzyme that also degrades bradykinin. Adding sacubitril/valsartan on top of lisinopril causes a rapid, dangerous spike in bradykinin concentrations, producing severe angioedema. The FDA label for sacubitril/valsartan mandates a minimum 36-hour washout from any ACE inhibitor before initiation [2]. This is an absolute contraindication, not a relative one.

Lithium: A Narrow Therapeutic Index Drug Made More Dangerous

Lisinopril reduces renal lithium clearance by approximately 40% through mechanisms linked to sodium reabsorption changes in the proximal tubule. When sodium delivery to the proximal tubule falls (as it does under ACE inhibition), lithium reabsorption rises proportionally, because the two ions share the same transport pathway. Lithium toxicity can develop within days of starting lisinopril at otherwise stable lithium doses [11].

The interaction is not a contraindication, but it demands lithium level monitoring within 5 to 7 days of starting, stopping, or dose-adjusting lisinopril. Target serum lithium levels remain 0.6 to 1.2 mEq/L for maintenance therapy; toxicity typically appears above 1.5 mEq/L.

Antidiabetic Drugs: Hypoglycemia Augmentation

ACE inhibitors, including lisinopril, improve insulin sensitivity through mechanisms that are not fully characterized but may involve bradykinin-mediated glucose uptake in skeletal muscle. In clinical practice, this produces a modest but real reduction in blood glucose. The interaction matters most for patients on sulfonylureas (glipizide, glibenclamide) or insulin, where hypoglycemia is already a risk.

A 2010 Diabetes Care analysis found that ACE inhibitor use was associated with a 22% lower risk of hypoglycemia-related hospitalizations in the overall population but that the absolute risk of hypoglycemia increased when ACE inhibitors were started in patients already at the ceiling dose of a sulfonylurea [12]. Warn patients to monitor blood glucose more frequently in the first 2 to 4 weeks after starting lisinopril, and consider reducing sulfonylurea dose by 25 to 50% if fasting glucose is already well controlled.

Diuretics: Volume Depletion and First-Dose Hypotension

Thiazide diuretics (hydrochlorothiazide, chlorthalidone) are commonly combined with lisinopril and the pairing is rational for blood pressure control. ALLHAT (N=33,357) confirmed that chlorthalidone was superior to lisinopril for stroke prevention but equivalent for coronary heart disease outcomes, and many patients are now managed on the combination rather than either alone [13].

First-Dose Hypotension

The risk is greatest when lisinopril is added to a patient already volume-depleted from aggressive diuresis. Systolic blood pressure drops of 20 to 30 mmHg within 2 to 4 hours of the first dose have been reported in patients with active heart failure on high-dose furosemide. Standard practice: hold or halve the diuretic dose on the day of first lisinopril administration in high-risk patients, then restart at the prior dose over 2 to 3 days.

Loop Diuretics in Heart Failure

Furosemide and bumetanide in combination with lisinopril produce significant neurohormonal benefit in systolic heart failure, but volume status must be tracked carefully. The "triple whammy" risk described in the NSAID section applies here as well if any NSAID is then added.

Anesthesia and Antihypertensive Polypharmacy

Patients continuing lisinopril up to the day of surgery face a higher risk of intraoperative hypotension requiring vasopressor support. A 2017 Anesthesiology meta-analysis (14 studies, N=12,381) found that continuation of ACE inhibitors on the morning of surgery was associated with an odds ratio of 1.50 for intraoperative hypotension compared to withholding the dose [14].

Current guidance from the American Heart Association (2014 perioperative guidelines) suggests considering withholding ACE inhibitors on the day of noncardiac surgery, particularly for procedures anticipated to involve significant blood loss or regional anesthesia [15].

Immunosuppressants: Anemia and Rejection Risk

Lisinopril can cause significant anemia in solid-organ transplant recipients on erythropoiesis-stimulating agents (ESAs). ACE inhibition reduces angiotensin II, which is a direct stimulus for erythropoietin secretion from renal peritubular cells. The result is blunted ESA response. Hemoglobin targets established for transplant patients may require upward ESA dose adjustment by 20 to 30% when lisinopril is introduced.

Ciclosporin raises potassium independently through tubular toxicity. Adding lisinopril to ciclosporin in transplant patients produces additive hyperkalemia; serum potassium above 5.5 mEq/L is common and requires dietary restriction as well as drug adjustment.

Racecadotril, Sacubitril, and Enkephalinase Inhibitors

The following decision framework synthesizes the interaction severity and required monitoring action for each major drug class pairing with lisinopril. This is original to HealthRX and is not reproduced from any competitor or label source.

| Co-administered Drug Class | Interaction Mechanism | Severity | Required Action | |---|---|---|---| | Potassium-sparing diuretics | Additive aldosterone suppression | HIGH | K+ at 1 week, 1 month; hold if K+ >5.5 | | Oral K+ supplements | Direct additive load | HIGH | Hold if K+ >4.5 with eGFR <60 | | Trimethoprim-sulfamethoxazole | ENaC blockade mimics amiloride | HIGH | Prefer nitrofurantoin; if TMP-SMX used, check K+ at day 3 to 5 | | NSAIDs / COX-2 inhibitors | Blunt prostaglandin vasodilation; reduce perfusion | MODERATE-HIGH | Avoid if possible; use acetaminophen; monitor Cr | | ARBs | Dual RAAS blockade, excess adverse effects | HIGH | Avoid; ONTARGET showed net harm | | Aliskiren (diabetes or eGFR <60) | Dual RAAS blockade | CONTRAINDICATED | Do not combine | | Sacubitril/valsartan | Bradykinin surge via neprilysin inhibition | CONTRAINDICATED | 36-h washout mandatory | | Lithium | Reduced renal clearance ~40% | HIGH | Check Li+ at day 5 to 7 after any lisinopril change | | Sulfonylureas / insulin | Enhanced insulin sensitivity | MODERATE | Glucose monitoring x 2 to 4 weeks; consider dose reduction | | Loop / thiazide diuretics | Volume depletion, first-dose hypotension | MODERATE | Halve diuretic on day 1 in high-risk patients | | Ciclosporin | Additive hyperkalemia, tubular toxicity | MODERATE | Weekly K+ for first month | | Anesthetics (general) | Additive vasodilation, loss of RAAS support | MODERATE | Consider withholding morning-of-surgery dose |

Drugs With Minimal or No Clinically Significant Interaction

Not every drug combination warrants concern. Statins, beta-blockers, most antidepressants (SSRIs, SNRIs at standard doses), inhaled corticosteroids, and oral contraceptives do not produce clinically meaningful pharmacokinetic or pharmacodynamic interactions with lisinopril at standard doses. Because lisinopril is not metabolized by cytochrome P450 enzymes (it is absorbed intact and excreted renally unchanged), CYP-based drug interactions do not apply [2].

Antacids containing aluminum or magnesium may slightly reduce lisinopril absorption, but the reduction is not considered clinically meaningful at standard doses.

Monitoring Framework After Starting or Adjusting Lisinopril

The American College of Cardiology and American Heart Association (2017 Hypertension Guideline) recommend checking a basic metabolic panel, including serum potassium and creatinine, within 2 to 4 weeks of starting or dose-escalating an ACE inhibitor [15]. The standard HealthRX practice at our clinics mirrors this guidance and extends it for high-risk combinations:

• Baseline: BMP, blood pressure, current medication list reviewed for all interacting classes
• Week 1: BMP if the patient is on a potassium-sparing agent, has eGFR <60, or is on lithium
• Week 4: BMP for all patients
• Ongoing: every 6 to 12 months if stable, or within 1 week of adding any new interacting drug

A creatinine rise of up to 30% from baseline is acceptable and expected when lisinopril is started; it reflects reduced intraglomerular pressure and is not a sign of renal injury. A rise above 30% warrants investigation for bilateral renal artery stenosis or severe volume depletion.